NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (REGN) Following Earnings And Buybacks, Is The Valuation Case Still Intact?
Regeneron Pharmaceuticals earnings, dividend and buybacks come into focus
Regeneron Pharmaceuticals (REGN) has drawn investor attention after reporting second quarter and six month 2026 results, affirming a quarterly dividend and outlining recent share repurchases. Together, these developments shape the current stock narrative.
See our latest analysis for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals shares have gathered momentum this year, with a 30 day share price return of 21.6% and...